Efficacy and Safety of Radiofrequency Ablation for Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.

IF 3.5 4区医学 Q2 SURGERY

Journal of Investigative Surgery Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI:10.1080/08941939.2025.2562263

Jiuxi Wu, Jian Wang, Jun Gao

{"title":"Efficacy and Safety of Radiofrequency Ablation for Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.","authors":"Jiuxi Wu, Jian Wang, Jun Gao","doi":"10.1080/08941939.2025.2562263","DOIUrl":null,"url":null,"abstract":"Objective: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of radiofrequency ablation (RFA) in the management of papillary thyroid cancer (PTC).Methods: A comprehensive literature search was conducted in the PubMed, Embase, Cochrane Library, Web of Science and CNKI databases. Studies reporting outcomes of RFA for PTC were included. Random-effects models were used for meta-analysis, and heterogeneity was assessed using I2 statistics.Results: Fifteen retrospective studies involving 1,844 patients were included. The meta-analysis revealed a pooled standardized mean difference of -1.11 (95% CI: -1.39 to -0.84) for volume reduction at 12 months, corresponding to an approximate 88.9% mean volume reduction, with moderate heterogeneity (I2 = 55.4%). The pooled risk ratio (RR) for complete disappearance was 1.08 (95% CI: 0.99-1.18), with significant heterogeneity among studies (I2 = 71.4%). The local recurrence rate was 0.62% (95% CI: 0.32%-1.21%), with no significant heterogeneity (I2 = 0.0%). The RFS analysis showed a pooled RR of 1.00 (95% CI: 0.93-1.08), with no significant heterogeneity (I2 = 0.0%). The local tumor progression rate was 1.42% (95% CI: 0.81%-2.48%), also with no significant heterogeneity (I2 = 0.0%).Conclusion: This meta-analysis suggests that RFA is an effective and safe treatment for PTC, demonstrating high volume reduction rates, satisfactory complete disappearance rates and low local recurrence rates.","PeriodicalId":16200,"journal":{"name":"Journal of Investigative Surgery","volume":"38 1","pages":"2562263"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08941939.2025.2562263","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of radiofrequency ablation (RFA) in the management of papillary thyroid cancer (PTC).

Methods: A comprehensive literature search was conducted in the PubMed, Embase, Cochrane Library, Web of Science and CNKI databases. Studies reporting outcomes of RFA for PTC were included. Random-effects models were used for meta-analysis, and heterogeneity was assessed using I² statistics.

Results: Fifteen retrospective studies involving 1,844 patients were included. The meta-analysis revealed a pooled standardized mean difference of -1.11 (95% CI: -1.39 to -0.84) for volume reduction at 12 months, corresponding to an approximate 88.9% mean volume reduction, with moderate heterogeneity (I² = 55.4%). The pooled risk ratio (RR) for complete disappearance was 1.08 (95% CI: 0.99-1.18), with significant heterogeneity among studies (I² = 71.4%). The local recurrence rate was 0.62% (95% CI: 0.32%-1.21%), with no significant heterogeneity (I² = 0.0%). The RFS analysis showed a pooled RR of 1.00 (95% CI: 0.93-1.08), with no significant heterogeneity (I² = 0.0%). The local tumor progression rate was 1.42% (95% CI: 0.81%-2.48%), also with no significant heterogeneity (I² = 0.0%).

Conclusion: This meta-analysis suggests that RFA is an effective and safe treatment for PTC, demonstrating high volume reduction rates, satisfactory complete disappearance rates and low local recurrence rates.

查看原文本刊更多论文

射频消融治疗甲状腺乳头状癌的疗效和安全性：一项系统综述和荟萃分析。

目的：本系统综述和荟萃分析旨在评价射频消融（RFA）治疗甲状腺乳头状癌（PTC）的有效性和安全性。方法：在PubMed、Embase、Cochrane Library、Web of Science和CNKI数据库中进行综合文献检索。研究报告了RFA治疗PTC的结果。采用随机效应模型进行meta分析，采用I2统计量评估异质性。结果：纳入15项回顾性研究，涉及1844例患者。荟萃分析显示，12个月时体积缩小的合并标准化平均差异为-1.11 (95% CI: -1.39至-0.84)，对应于大约88.9%的平均体积缩小，具有中等异质性（I2 = 55.4%）。完全消失的合并风险比（RR）为1.08 (95% CI: 0.99-1.18)，研究间存在显著异质性（I2 = 71.4%）。局部复发率为0.62% (95% CI: 0.32% ~ 1.21%)，无显著异质性（I2 = 0.0%）。RFS分析显示，合并RR为1.00 (95% CI: 0.93-1.08)，无显著异质性（I2 = 0.0%）。局部肿瘤进展率为1.42% (95% CI: 0.81% ~ 2.48%)，也无显著异质性（I2 = 0.0%）。结论：本荟萃分析表明RFA治疗PTC有效且安全，具有高体积缩小率，令人满意的完全消失率和低局部复发率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative Surgery 医学-外科

CiteScore

4.20

自引率

0.00%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Journal of Investigative Surgery publishes peer-reviewed scientific articles for the advancement of surgery, to the ultimate benefit of patient care and rehabilitation. It is the only journal that encompasses the individual and collaborative efforts of scientists in human and veterinary medicine, dentistry, basic and applied sciences, engineering, and law and ethics. The journal is dedicated to the publication of outstanding articles of interest to the surgical research community.